$SPRCAug 12, 2026, 12:25 PMAI processed
SciSparc subsidiary NeuroThera wins Japanese patent for paracetamol + N‐acylethanolamine combo
AI Summary
SciSparc said its majority-owned subsidiary NeuroThera Labs (NTLX) was granted a Japanese patent titled "Compositions and Methods for Potentiating Derivatives of 4‐Aminophenols," covering proprietary combinations of 4‐aminophenol derivatives (including paracetamol) with N‐acylethanolamines. The company says the combos are intended to enhance analgesic/antipyretic effects and may allow lower dosing to mitigate dose‐related side effects, and the grant expands NeuroThera/SciSparc’s IP footprint in Japan — commercial value still depends on clinical data, regulatory approvals, and commercialization steps.
Positives
- Japanese patent granted covering combinations of 4‑aminophenol derivatives (eg paracetamol) with N‑acylethanolamines
- Patent strengthens NeuroThera/SciSparc IP portfolio and adds geographic protection in Japan
- Company claims the combination could enhance efficacy and potentially enable lower dosing, which could address dose‑related side effects
Negatives
- Patent grant is not clinical proof — efficacy and safety benefits remain unproven until clinical data are reported
- No regulatory approvals or commercialization milestones announced alongside the patent
- Claims about dosing and side‑effect reduction are forward‑looking and subject to clinical and regulatory risk